mutLBSgeneDB |
Gene summary for UCHL1 |
![]() |
Basic gene Info. | Gene symbol | UCHL1 |
Gene name | ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) | |
Synonyms | HEL-117|NDGOA|PARK5|PGP 9.5|PGP9.5|PGP95|Uch-L1 | |
Cytomap | UCSC genome browser: 4p14 | |
Type of gene | protein-coding | |
RefGenes | NM_004181.4, | |
Description | epididymis luminal protein 117neuron cytoplasmic protein 9.5ubiquitin C-terminal hydrolaseubiquitin carboxyl-terminal hydrolase isozyme L1ubiquitin thioesterase L1 | |
Modification date | 20141207 | |
dbXrefs | MIM : 191342 | |
HGNC : HGNC | ||
Ensembl : ENSG00000154277 | ||
HPRD : 01877 | ||
Vega : OTTHUMG00000099377 | ||
Protein | UniProt: P09936 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_UCHL1 | |
BioGPS: 7345 | ||
Pathway | NCI Pathway Interaction Database: UCHL1 | |
KEGG: UCHL1 | ||
REACTOME: UCHL1 | ||
Pathway Commons: UCHL1 | ||
Context | iHOP: UCHL1 | |
ligand binding site mutation search in PubMed: UCHL1 | ||
UCL Cancer Institute: UCHL1 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0016579 | protein deubiquitination | 9521656 | GO:0043407 | negative regulation of MAP kinase activity | 19477270 |
Top |
Ligand binding site mutations for UCHL1 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | H161 | H161Y | SKCM | 3 | R178 | P180S | STAD | 1 | R153 | R153Q | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for UCHL1 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R178 | P180S | -1.0706589 | R153 | R153Q | -1.0682844 | H161 | H161Y | -0.58119278 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
PDB ID | PDB title | PDB structure | 2ETL | Crystal Structure of Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) | ![]() |
Top |
Differential gene expression and gene-gene network for UCHL1 |
![]() |
![]() |
Top |
Top |
Phenotype information for UCHL1 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0007131 | Carcinoma, Non-Small-Cell Lung | 4 | Biomarker |
umls:C2239176 | Carcinoma, Hepatocellular | 2 | AlteredExpression, Biomarker |
umls:C0014859 | Esophageal Neoplasms | 2 | Biomarker |
umls:C0016978 | Gallbladder Neoplasms | 1 | Biomarker |
umls:C0019284 | Hernia, Diaphragmatic | 1 | Biomarker |
umls:C0031117 | Peripheral Nervous System Diseases | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for UCHL1 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GVE | METHYL 4-AMINOBUTANOATE | 3kvf | A | H161 | GVE | METHYL 4-AMINOBUTANOATE | 3kw5 | A | H161 | III | Peptide ligand (PHQ,VAL,ALA,GLU,CF0) | 4dm9 | A | R153 R178 | III | Peptide ligand (PHQ,VAL,ALA,GLU,CF0) | 4dm9 | B | R153 R178 |
Top |
Conservation information for LBS of UCHL1 |
![]() |
LBS | AA sequence | # species | Species | A57 | LFPLTA----- | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A57 | LFPLTAQRCFK | 1 | Bos taurus | C90 | TIGNSCGTIGL | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | F160 | DDKVNFHFILF | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | G87 | MKQTIGNSCGT | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | H161 | DKVNFHFILFN | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | I8 | LKPMEINPEML | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | K157 | CRVDDKVNFHF | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | L52 | CALLLLFPLTA | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | L55 | LLLFPLTA--- | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L55 | LLLFPLTAQRC | 1 | Bos taurus | N159 | VDDKVNFHFIL | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | N88 | KQTIGNSCGTI | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | Q84 | VYFMKQTIGNS | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | R153 | QEGQCRVDDKV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | R178 | YELDGRMPFPV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | S89 | QTIGNSCGTIG | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | V158 | RVDDKVNFHFI | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |